SMC3 and acute myeloid leukemia: With regard to survival times, again no difference was found both for patients with SMC1A-mutated vs. SMC1A-wildtype AML (Fig. 3C-E) as well as patients with SMC3 mutations when compared to their wildtype counterparts (Fig. 4C-E).